TransGenomic Corporation Accelerates Acquisition of IMAT Funded Technology

Transgenomic has announced that it has licensed a high-sensitivity mutation detection technology called Cold-PCR from the Dana-Farber Cancer Institute (DFCI) in Boston.

This variation of the standard PCR technology enriches mutations in DNA samples and is a much more sensitive technique for finding low-level mutations in tissue and body fluids that are involved with a variety of diseases. Cold-PCR was invented at DFCI by Dr Mike Makrigiorgos, an multi-award IMAT grantee, who has demonstrated its effectiveness in enriching for mutations in cancer-related genes in samples where standard DNA sequencing is not sensitive enough to detect these very low concentration somatic DNA mutations. Read more about Cold-PCR technology here.